ResearcherSapporo Hokuyu HospitalNo recent work listed

Kazuhiro Nagai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0002-2335-4381; OpenAlex author ID A5009218723. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 10

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper

Papers 3

Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Res… Co-author DOI 10.21873/anticanres.14593 ↗
WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. Co-author DOI 10.21873/anticanres.12464 ↗
Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Co-author DOI 10.1007/s00262-014-1554-7 ↗

Closest collaborators

The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Haruo Sugiyama · 2 shared papers, 2018–2020 · strength 0.21
- Paper Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic … DOI 10.21873/anticanres.14593 ↗
- Paper WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. DOI 10.21873/anticanres.12464 ↗
Susumu Eguchi · 1 shared paper, 2020 · strength 0.13
- Paper Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic … DOI 10.21873/anticanres.14593 ↗
Yasushi Miyazaki · 1 shared paper, 2020 · strength 0.13
- Paper Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic … DOI 10.21873/anticanres.14593 ↗
Masato Okamoto · 2 shared papers, 2014–2018 · strength 0.11
- Paper WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. DOI 10.21873/anticanres.12464 ↗
- Paper Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving ch… DOI 10.1007/s00262-014-1554-7 ↗
Shigetaka Shimodaira · 2 shared papers, 2014–2018 · strength 0.11
- Paper WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. DOI 10.21873/anticanres.12464 ↗
- Paper Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving ch… DOI 10.1007/s00262-014-1554-7 ↗
Shigeo Koido · 1 shared paper, 2018 · strength 0.08
- Paper WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. DOI 10.21873/anticanres.12464 ↗
Ryu Yanagisawa · 1 shared paper, 2018 · strength 0.08
- Paper WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study. DOI 10.21873/anticanres.12464 ↗
Yoshikazu Yonemitsu · 1 shared paper, 2014 · strength 0.04
- Paper Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving ch… DOI 10.1007/s00262-014-1554-7 ↗
Masahiro Ogasawara · 1 shared paper, 2014 · strength 0.04
- Paper Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving ch… DOI 10.1007/s00262-014-1554-7 ↗
Yuta Shibamoto · 1 shared paper, 2014 · strength 0.04
- Paper Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving ch… DOI 10.1007/s00262-014-1554-7 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.